Clinical Symposium held on “Deeper Insights in Haematology”; Erba H7100 brings hope for early and accurate diagnosis of blood disorders
Bengaluru, January 27th, 2025: Erba Transasia Group, India’s No. 1 In-vitro Diagnostic (IVD) Company and among the leading global IVD players focused on emerging markets, today introduced Erba H7100 – its advanced Haematology Analyzer at a Clinical Symposium held in Bengaluru on the theme “Need for High-End Haematology Analyzers to tackle current challenges faced by clinical laboratories.” Dr. Anil Handoo, Principal Director and Head – Laboratory Services, BLK-Max Superspeciality Hospital, Delhi, delivered the keynote address, joined by an expert panel that included Dr. Swati Pai – Consultant Haematopathologist, Manipal Hospitals; Dr. Leena Appicatlaa, Head – Laboratory Operations, Triesta Sciences, HCG Hospital Group; Dr. Madhusmita Jena, Professor and Head – Pathology, East Point of College of Medical Sciences & Research Centre; Dr. Shridhar Murthy, Lead Consultant, Head – Laboratory & Blood Centre, Aster Labs, Aster CMI Hospital and Dr. Hareesha Babu K, Nephrologist as the panelist.
With a rise in the number of cancer patients receiving treatment in hospitals, Karnataka Chief Minister Siddaramaiah has instructed Medical Education Department officials to conduct a study to identify the reasons for the increase in the number of people suffering from the disease in the State. This underscores the need for advanced haematology analyzers.
Equipped with fluorescence flow cytometry technology, the Erba H7100 offers a 70-parameter range, including Reticulocytes, Immature Platelet Fraction (IPF), and Immature Granulocytes (IG). These parameters are essential for diagnosing and treating conditions such as anaemia, thrombocytopenia, infections, inflammation, and blood cancers.
Dr. Anil Handoo remarked, “Karnataka’s diverse population and unique health concerns require precise diagnostic solutions like the Erba H7100. This analyzer is a step forward in addressing diagnostic gaps, especially for underserved communities battling hereditary disorders like thalassemia.”
The Erba H7100 is a breakthrough in haematology diagnostics, redefining the field by enabling rapid, reliable insights for clinicians and enhancing diagnostic accuracy and research capabilities.
Talking on the launch, Suresh Vazirani, Founder Chairman, Erba Transasia Group, said, “Our commitment to advancing healthcare through innovation is exemplified in Erba H7100 Haematology Analyzer which stands out with its unique capabilities, providing an extensive panel of clinical and research parameters. Its cost-effective and minimizing reagent usage is ideal for large and medium-sized labs, corporate hospitals and B2B labs. We are confident Erba H7100 will revolutionize haematology diagnostics, providing clinicians with the tools they need to drive better outcomes.”
Elaborating further, Vijay Kumar, CCO and Country Head, Transasia Bio-Medicals Ltd said:, “Erba H7100 set itself apart with a throughput of 90 tests per hour for CBC+diff and 70 tests per hour for CBC+Diff+retics. Fully automated, it can become a 2X system by adding additional units and samplers. Its Mentzer Index feature helps differentiate between Iron Deficiency Anemia (IDA) and Beta Thalassemia while its Optical Platelet (Plt-O) feature addresses challenges like pseudo-thrombocytopenia in haematological analysis. Optical platelet count reduces the spurious count and is useful in correcting spurious low platelet counts in EDTA-PTCP patients. By addressing many challenges that labs and pathologists face, we help healthcare professionals offer to patients, the best possible care.”
A key focus of the symposium was the clinical significance of incorporating reticulocyte parameters into haematology analyzers allowing clinicians to differentiate between various types of anaemia, classify them based on underlying mechanisms and customize treatment strategies accordingly. These advanced parameters also aid in assessing the effectiveness of interventions like iron therapy, erythropoietin administration and blood transfusions, ultimately enhancing patient care. The symposium highlighted the prognostic value of reticulocyte parameters in conditions like chronic kidney disease, chemotherapy-induced anaemia and haematological malignancies. Monitoring these parameters is vital in evaluating disease progression, predicting complications, and adjusting treatment regimens. In clinical laboratories, the integration of these advanced parameters leads to faster, more accurate diagnostics and improved efficiency, streamlining workflows and reducing turnaround time. Haematology analyzers are extensively used in patient and research settings to count and characterize blood cells for disease detection and monitoring.
